Humanin for Health & Longevity

Evidence Review created on 08/06/2026 using AI4L / Opus 5

Also known as: HN, MT-RNR2, S14G-humanin, HNG, HNGF6A, Colivelin

Motivation

Humanin is a very short protein fragment that cells build from genetic instructions held inside mitochondria, the internal compartments that supply cells with energy. Almost every other protein in the body is coded in the cell nucleus; this one is not. Once made, it leaves the cell, travels in the bloodstream, and appears to work as a signal carrying news about mitochondrial condition to the rest of the body.

It was found by chance in brain tissue that had survived where neighboring tissue had died. Interest widened when researchers noticed that the amount circulating in blood tends to fall as people age, and that unusually long-lived families tend to carry more of it. Animals given a synthetic version look metabolically healthier. Other researchers read the same pattern in reverse, arguing that a rise in this signal marks cells under strain rather than cells that are thriving.

This review examines humanin’s biology, the strength of the evidence behind each proposed benefit, the risks and open questions attached to a compound that has never been given to a person in a registered trial, and the practical realities of sourcing and monitoring.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Humanin

A dense, well-sourced single-page overview covering the peptide sequence, the receptor complexes, the age-related decline in circulating levels and the disease areas under study. It is the fastest route to a technically accurate orientation before reading the primary literature.

Examine

No Examine article exists for humanin. Examine.com covers dietary supplements and food-derived compounds, and does not cover research-grade peptides that are not sold as supplements.

ConsumerLab

No ConsumerLab article or product review exists for humanin. ConsumerLab tests consumer supplement products; humanin is not sold as a supplement in any regulated market, so no product exists to test.

Systematic Reviews

The systematic review literature on humanin is extremely thin, and the single qualifying paper is summarized here.

Humanin and Its Pathophysiological Roles in Aging: A Systematic Review - Coradduzza et al., 2023

The only systematic review dedicated to humanin. It synthesizes the mechanistic and observational literature linking the peptide to cellular senescence, cardiovascular disease, neurodegeneration and cancer, and is candid that the underlying studies are overwhelmingly preclinical, so no pooled effect estimate is possible.

Note on the number of entries: Only one systematic review of humanin exists. A second review with meta-analysis covering mitochondrial-derived peptides was identified, but it pools data on MOTS-c rather than humanin and was therefore excluded as not relevant to this intervention. No further systematic reviews or meta-analyses of humanin were found on PubMed as of August 6, 2026.

Mechanism of Action

Humanin is a mitochondrial-derived peptide — a small protein fragment coded by genes inside the mitochondria rather than in the cell nucleus. Its instructions sit in a short open reading frame (a stretch of genetic code that can be read as a protein) inside the MT-RNR2 gene, which otherwise codes for part of the mitochondrial protein-building machinery. Translated inside the mitochondrion it is 21 amino acids long; translated in the surrounding cell fluid it is 24. It carries no conventional export tag, yet it is secreted and is measurable in plasma, cerebrospinal fluid, semen and ovarian follicular fluid.

It acts through two largely separate routes.

Inside the cell (anti-apoptotic route): humanin binds directly to the proteins that execute programmed cell death — BAX, BID and BIM — and prevents them from perforating the mitochondrial membrane and releasing cytochrome c. It also binds IGFBP-3 (insulin-like growth factor binding protein 3, the main carrier protein that controls how much growth factor reaches tissues). Independent work has shown that the S14G analog additionally behaves like a molecular chaperone, holding misfolded proteins in a soluble state, as reported in The Mitochondrial-Derived Peptides, HumaninS14G and Small Humanin-like Peptide 2, Exhibit Chaperone-like Activity. It also acts as an inducer of autophagy — the cell’s system for digesting and recycling its own damaged components — raising the expression of autophagy-related genes, sustaining autophagic flux rather than triggering it once, and lowering the accumulation of misfolded proteins in mouse skeletal muscle (Humanin-induced autophagy plays important roles in skeletal muscle function and lifespan extension).
Outside the cell (receptor route): secreted humanin binds a three-part surface receptor made of CNTFR (ciliary neurotrophic factor receptor), WSX-1 (a subunit of the interleukin-27 receptor) and gp130 (a shared signaling unit used by the interleukin-6 family of immune messengers), documented in Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130. It separately activates FPRL1 (formyl peptide receptor-like 1, an immune-cell receptor also used by amyloid-beta), shown in Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. Downstream this switches on STAT3, ERK1/2 and AKT — three signal-relay proteins that together tell a cell to survive, grow and take up glucose — as mapped in The mitochondrial-derived peptide humanin activates the ERK1/2, AKT, and STAT3 signaling pathways and has age-dependent signaling differences in the hippocampus.
Metabolic signaling (a downstream consequence of the receptor route): infused into the brain, humanin activates STAT3 in the hypothalamus and improves whole-body insulin action; blocking hypothalamic STAT3 abolishes the effect on the liver, indicating the liver response is brain-mediated rather than direct (Humanin: a novel central regulator of peripheral insulin action).

Competing mechanistic interpretations. Two readings of the same data compete, and both remain live.

The protective-signal reading: humanin is a genuine cytoprotective hormone. Levels fall with age, restoring them restores stress resistance, and long-lived organisms hold higher levels. This is the interpretation advanced by the groups that discovered the peptide.
The strain-marker reading: humanin is a distress flare. Its release is triggered by mitochondrial damage, so a high level reports a damaged system rather than a protected one. On this reading humanin is a mitokine (a signal released by mitochondria to report their condition to the rest of the body). Human Aging and Longevity Are Characterized by High Levels of Mitokines found humanin rising with age and associating with weaker grip strength, worse insulin sensitivity and — in the oldest participants — shorter survival. The commentary Mitochondrial-Derived Peptides Exacerbate Senescence extends this, arguing the peptide keeps senescent cells alive and increases their inflammatory output.
A measurement caveat that bears on both readings: the human nuclear genome contains a family of humanin-like pseudogenes (MTRNR2L1 through MTRNR2L13) producing near-identical sequences. Antibody-based assays cannot reliably separate their products from true mitochondrial humanin, so some of the reported “circulating humanin” may not be mitochondrial in origin. This is an unresolved technical objection, not a refutation, and neither camp has produced assay data that settles it.

Pharmacological properties. Humanin is a peptide, so it is not metabolized by the cytochrome P450 enzyme system that handles most oral drugs; it is cleared by peptidases and renal filtration, and no cytochrome-mediated drug interactions are expected. Its circulating half-life is approximately 30 minutes. Rodent pharmacokinetic work in Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents found that the half-life is longer in rats than mice, that the non-IGFBP-3-binding analog HNGF6A persists longer than S14G-humanin, and that after peripheral injection the peptide is highest in plasma, present in liver, and undetectable in brain or heart — meaning central effects seen after peripheral dosing are unlikely to reflect direct brain exposure. Selectivity is limited: gp130 and FPRL1 are both broadly expressed, so tissue targeting is poor. It has no oral bioavailability.

Historical Context & Evolution

Original intended use. Humanin was not sought as a longevity agent. It was isolated in 2001 by a Japanese group screening a complementary DNA library built from the occipital lobe of an Alzheimer’s patient — a region that had survived while others degenerated — looking for anything that could rescue neurons from familial Alzheimer’s mutations. The founding paper, A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta, reported a 24-amino-acid peptide that blocked neuronal death from every familial Alzheimer’s gene tested. The intended application was a neuroprotective drug for dementia, and the first decade of work was almost entirely neurological.
The engineered analogs came early. Within a few years, substituting glycine for serine at position 14 produced S14G-humanin (HNG), a far more potent variant, and fusing humanin to a fragment of activity-dependent neurotrophic factor produced colivelin. Almost all subsequent in vivo work uses these analogs rather than the natural peptide, which matters when interpreting the literature: S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice and Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer’s disease both tested engineered molecules.
The pivot to metabolism and aging. The move from neurology to longevity happened in 2009, when clamp studies (the reference laboratory method for measuring how strongly the body responds to insulin) showed humanin regulating insulin action from the hypothalamus and, critically, that circulating levels decline with age in both rodents and humans. This reframed the peptide from a neuroprotective curiosity into a candidate age-related signaling molecule and pulled it into the gerontology literature.
The growth-axis link. IGF-I regulates the age-dependent signaling peptide humanin then connected humanin to the best-established endocrine longevity pathway. Long-lived, growth-hormone-deficient Ames dwarf mice carried elevated humanin; short-lived growth-hormone-transgenic mice carried less; and giving growth hormone or IGF-1 (insulin-like growth factor 1, the main growth signal driven by growth hormone) to mice or humans lowered circulating humanin. Humanin thereby acquired a plausible position downstream of the growth axis that dominates comparative longevity biology.
The discovery of a wider family. In 2015 and 2016 the same research program identified MOTS-c and six small humanin-like peptides, establishing mitochondrial-derived peptides as a class rather than a one-off finding. Humanin stopped being an anomaly and became the founding member of a category.
Who funded the field, and where the financial interests sit. A large share of the humanin and mitochondrial-derived peptide literature originates from one research program at the USC Leonard Davis School of Gerontology, whose senior investigators Pinchas Cohen and Nir Barzilai are disclosed consultants and stockholders of CohBar Inc., a company established to develop these peptides into drugs and later absorbed into another biotechnology company. That is a direct financial interest in the intervention being adopted, and it is relevant to which molecules were engineered, which endpoints were pursued and which negative results were emphasized. The interest runs one way only: no professional association, medical society or advocacy organization derives revenue from humanin being rejected, and no organized body has taken a position for or against it, so there is no counterweight of the kind found in contested clinical fields. On the payer side, no insurer or national health system has any financial stake in humanin, because it is not reimbursed anywhere and competes with no reimbursed therapy — meaning the structural bias that shapes guideline formation for cost-differentiated treatments is absent here. What replaces it is patent economics: analogs that can be patented attract development capital, while the natural 24-amino-acid peptide, which cannot, does not, and that asymmetry rather than payer preference explains why nearly all in vivo evidence concerns engineered variants. The dissenting sources cited in this review, including Mendelsohn and Larrick, disclose no competing financial interest in humanin.
How scientific opinion has shifted, and what remains open. The early neuroprotective findings have never been overturned; the cell and animal results replicate across many independent laboratories. What has changed is the interpretation of the human data. The claim that humanin declines with age and that decline is harmful was strengthened by cohort work but complicated by the mitokine data showing the peptide rising with age and tracking worse outcomes in the oldest subjects. The authors of the lifespan study themselves note that human association studies have been equivocal. The pseudogene-crossreactivity objection to the immunoassays has been raised repeatedly and has not been resolved by either side; it is a legitimate methodological challenge that has not been converted into direct evidence that published measurements are wrong. No part of the founding literature has been retracted or shown to be irreproducible. The current position is therefore best described as a robust preclinical body whose human interpretation is genuinely contested, rather than a field that has moved on.

Expected Benefits

Evidence grades reflect what is known about humanin in a person who might actually use it: an informed adult acting on preclinical data, since no human interventional trial exists.

High 🟩 🟩 🟩

No proposed benefit of humanin currently reaches this threshold. High would require consistent human interventional evidence, and no trial has ever administered humanin or an analog to a person.

Medium 🟩 🟩

Association With Exceptional Longevity and Slower Cognitive Aging ⚠️ Conflicted

Higher circulating humanin tracks with familial longevity and with better preservation of cognition. The children of centenarians — a group with lower mortality and disease burden than age-matched peers — carry substantially higher levels, and a mitochondrial genetic variant that lowers humanin production is associated with measurably faster cognitive aging in a large representative cohort of older adults, which is a genetic rather than merely correlational line of support. The proposed mechanism is preserved mitochondrial signaling and reduced neuronal apoptosis. The evidence is human but entirely observational, and it is directly contradicted by mitokine cohort data in which humanin rises with age and associates with worse function and shorter survival in the very old, so causal direction is unresolved.

Magnitude: Children of centenarians (n=18) had significantly higher circulating humanin than age-matched controls (n=19); levels fall roughly 40% over the first 18 months of life in mice and drop sharply in rhesus macaques between 19 and 25 years of age; carriers of the mitochondrial variant rs2854128 show lower circulating humanin and accelerated cognitive aging (Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans).

Neuroprotection Against Alzheimer-Type and Ischemic Injury

Humanin and its analogs protect neurons from amyloid-beta toxicity, familial Alzheimer’s mutations, glutamate excitotoxicity (nerve cells being killed by overstimulation from the messenger glutamate) and ischemia (tissue starved of blood flow). The mechanism is dual: blockade of the apoptotic machinery inside neurons, and competition with amyloid-beta for the FPRL1 receptor on immune cells in the brain. The evidence basis is large and unusually well replicated — dozens of independent laboratories, multiple human cell models and several transgenic mouse lines — which is why this is graded above the other preclinical benefits. The limitation is decisive, however: every positive in vivo result used an engineered analog, and none of it has been tested in a person.

Magnitude: S14G-humanin improved cognitive performance and reduced amyloid pathology in middle-aged transgenic Alzheimer mice, and intranasal colivelin reversed memory impairment in comparable models; cerebrospinal fluid humanin was lower in Alzheimer’s patients than controls in a very small sample (n=3 versus n=4), and a recent human biomarker study reports the same directional finding (Insights into the Biomarker Potential of Humanin and Mots-c Expression and Telomere Length in Alzheimer’s Disease). No human treatment effect size exists.

Improved Insulin Sensitivity and Body Composition ⚠️ Conflicted

Humanin acts as an insulin sensitizer through the hypothalamus and directly supports insulin secretion from pancreatic beta cells. The mechanism runs through hypothalamic STAT3 signaling for the liver component and through enhanced beta-cell metabolism for the secretory component, demonstrated in Potent humanin analog increases glucose-stimulated insulin secretion through enhanced metabolism in the β cell. The evidence basis is gold-standard rodent physiology — hyperinsulinemic-euglycemic clamp studies, the most rigorous available method — reproduced across several models, plus human association data linking lower humanin to higher long-term blood sugar and triglycerides. It is flagged as conflicted because the human correlational arm points both ways: the mitokine cohort finds the opposite association, with higher humanin tracking worse insulin sensitivity and higher triglycerides, particularly in 70-year-olds. All interventional data remain rodent, so the direction of the human relationship is unresolved.

Magnitude: Brain infusion of humanin markedly increased whole-body insulin sensitivity in rodent clamp studies and a single dose of a potent analog lowered blood glucose in Zucker diabetic fatty rats; in 18-month-old mice, S14G-humanin at 4 mg/kg twice weekly for 14 months reduced visceral fat and increased lean mass with no change in food intake.

Low 🟩

Cardioprotection in Ischemia–Reperfusion Injury ⚠️ Conflicted

Given at the time of reperfusion, S14G-humanin limits the amount of heart muscle lost after a blocked artery is reopened, apparently by suppressing heart muscle cell apoptosis and oxidative injury. The evidence basis includes a large-animal study, which is a meaningful step above rodent work. It is graded Low and flagged as conflicted because the same study found the benefit vanished when the ischemic period was lengthened to a more clinically realistic duration — the effect exists but is fragile and window-dependent. Separately, circulating humanin is lower in people with coronary disease and predicts subsequent cardiac events, which is a biomarker observation rather than evidence that supplementation helps.

Magnitude: S14G-humanin at 2 mg/kg reduced infarct size in pigs after 60 minutes of coronary occlusion but produced no benefit after longer ischemia (Efficacy of a Novel Mitochondrial-Derived Peptide in a Porcine Model of Myocardial Ischemia/Reperfusion Injury); across 327 patients, serum humanin averaged 157.77 ± 99.93 pg/mL in controls, 124.22 ± 63.02 pg/mL in angina and 67.17 ± 24.35 pg/mL after myocardial infarction (Circulating humanin is lower in coronary artery disease and is a prognostic biomarker for major cardiac events in humans).

Long-term treatment with an analog reduces the scar-like stiffening of heart muscle that accumulates with age, which is one of the mechanisms behind the age-related loss of cardiac filling capacity. The proposed mechanism is suppression of cardiac fibroblast proliferation and of the fibrotic signals those cells release, together with reduced heart muscle cell apoptosis, apparently through AKT signaling. The evidence basis is a single long-term rodent experiment — the same 14-month aged-mouse protocol that produced the body composition findings — which is why it is graded Low, and it uses only female animals of one strain. This endpoint is directly relevant to a longevity-oriented user because age-related cardiac fibrosis is a structural change that no widely used intervention reverses, but no human or large-animal data exist.

Magnitude: In female mice given S14G-humanin at 4 mg/kg twice weekly from 18 to 32 months of age, cardiac collagen deposition, fibroblast proliferation and myocardial apoptosis were all significantly reduced relative to untreated aged controls (Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice).

Preservation of Endothelial Function and Restraint of Plaque Progression

Humanin is expressed in the endothelium — the single-cell lining of blood vessels — and long-term treatment with an analog preserves the lining’s function and slows atherosclerotic plaque build-up. The mechanism is reduction of oxidative stress and of programmed cell death within the developing plaque, with preserved production of the enzyme that generates nitric oxide, the molecule vessels use to relax; notably the effect is not mediated by lowering cholesterol. The evidence basis is a single long-term rodent study plus supporting cell work, which is why it is graded Low, and it is consistent with the human observation that circulating humanin is lower in people with coronary disease. No human or large-animal atherosclerosis experiment has been performed.

Magnitude: Sixteen weeks of daily HNGF6A injection reduced atherosclerotic plaque size in the proximal aorta and prevented endothelial dysfunction in a mouse strain bred to develop atherosclerosis on a high-cholesterol diet, compared with untreated controls, with no change in blood cholesterol (Humanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice).

Protection of Bone Growth and Restraint of Bone Resorption

Humanin shields the growth plate from drug-induced damage and dampens the cells that dissolve bone. The mechanism is twofold: it prevents apoptosis in growth-plate cartilage cells and restores Indian Hedgehog signaling — the developmental pathway that paces long-bone growth — as shown in Humanin is a novel regulator of Hedgehog signaling and prevents glucocorticoid-induced bone growth impairment, while separately blocking the differentiation of osteoclasts, the cells responsible for bone resorption (Humanin suppresses receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation via AMP-activated protein kinase activation). The evidence basis is several independent animal and cultured-bone studies, all preclinical, which is why it is graded Low; importantly, the protective effect did not blunt the intended anti-inflammatory action of the steroid it was protecting against. This benefit is most relevant to users exposed to bone-hostile drugs rather than to healthy adults, and no human bone endpoint has been tested.

Magnitude: In tumor-bearing mice, the anticancer drug bortezomib cut linear bone growth from 0.19 mm/day in untreated controls to 0.09 mm/day, and adding the humanin analogue restored it to 0.15 mm/day without blunting the anticancer effect (Eriksson et al., 2014).

Protection of Retinal Pigment Epithelium

Humanin protects the retinal pigment epithelium — the support layer beneath the retina whose failure drives age-related macular degeneration — from oxidative and endoplasmic reticulum stress (strain caused by a build-up of misfolded proteins inside the cell), preserving mitochondrial membrane potential and preventing cell death. The evidence basis is in vitro only, but it includes hybrid cell lines carrying mitochondria from actual macular degeneration donors, which is a stronger model than standard cell culture. The obvious limitation is that no animal or human eye has been treated, and delivery to the retina would require intraocular or nanoparticle formulation rather than systemic dosing.

Magnitude: Not quantified in available studies.

Protection of Reproductive Tissue and Gamete Quality ⚠️ Conflicted

Humanin is abundantly expressed in testis and ovary and shields germ cells from chemotherapy and oxidative injury; in men, seminal plasma humanin correlates with sperm quality parameters. The mechanism involves the interleukin-27 receptor components, established in The IL-27 component EBI-3 and its receptor subunit IL-27Rα are essential for the cytoprotective action of humanin on male germ cells. Evidence is animal and human-observational; it is graded Low because the human data are cross-sectional associations and because the same body of work contains an apparently opposite finding, namely that animals engineered to overproduce humanin have reduced reproductive output.

Magnitude: Not quantified in available studies.

Resolution of Inflammation ⚠️ Conflicted

Humanin appears to participate in switching off inflammation rather than merely suppressing it. Human macrophages clearing dead cells release humanin, which then promotes the resolution phase — a mechanism recently described in HUMANIN produced by human efferocytic macrophages promotes the resolution of inflammation. In aged mice, long-term analog treatment reduced inflammatory markers. Evidence is early and mechanistic, with one human cell system and one rodent model, and it sits uncomfortably alongside the finding that the same peptides increase inflammatory secretion from senescent cells.

Magnitude: Not quantified in available studies.

Induction of Autophagy and Clearance of Misfolded Proteins

Humanin switches on autophagy — the cell’s system for digesting and recycling its own damaged components — and keeps that process running rather than triggering it once. The mechanism is increased expression of autophagy-related genes, and this route carries the peptide’s lifespan effect in nematodes, since blocking autophagy abolishes it. The evidence basis is a single multi-model study spanning three cell lines, mice and Caenorhabditis elegans, which is why it is graded Low; it remains entirely preclinical and comes from the discovering research program rather than an independent group. This endpoint is relevant to a longevity-oriented user because declining autophagic capacity is one of the more consistently identified features of aging, and it also sits directly against the concern that humanin blocks useful cellular housekeeping.

Magnitude: Humanin administration raised autophagy-related gene expression and reduced the accumulation of misfolded proteins in mouse skeletal muscle, and autophagy was required for humanin-induced lifespan extension in Caenorhabditis elegans (Humanin-induced autophagy plays important roles in skeletal muscle function and lifespan extension).

Speculative 🟨

Extension of Lifespan

Overexpressing humanin extends lifespan in the nematode Caenorhabditis elegans, and the effect depends on daf-16, the worm equivalent of the FOXO family of stress-resistance and longevity genes — a clean mechanistic result. The basis for extending this to humans is entirely speculative: in mice, 14 months of analog treatment starting in mid-life produced no lifespan extension at all, only healthspan improvements. The authors attribute this to the peptide’s 30-minute half-life and to treatment starting too late, but those are hypotheses rather than findings. No controlled lifespan data exist in any mammal.

Preservation of Skeletal Muscle Mass

Humanin, alongside MOTS-c, blunts steroid-induced wasting in human skeletal muscle cells, suggesting a role in protecting muscle during catabolic stress (Mitochondrial-derived peptides MOTS-c and humanin attenuate dexamethasone-induced atrophy in human skeletal muscle cells). The direct basis for the mass endpoint is a single recent cell-culture study; mouse work in which humanin raised autophagy-gene expression and lowered misfolded-protein accumulation in skeletal muscle supports the tissue but did not measure mass, and the aged-mouse lean-mass finding is confounded by simultaneous fat loss. No human muscle endpoint has been tested, so this remains mechanistic plausibility only.

Benefit-Modifying Factors

Mitochondrial genetic variants (rs2854128): carriers of this variant in the humanin coding region of the mitochondrial genome produce less circulating humanin and show faster cognitive aging. Because mitochondrial DNA is maternally inherited, this is testable from any mitochondrial haplogroup report, and carriers arguably have the largest theoretical headroom for benefit from restoring levels.
The P3S variant and APOE4 status: APOE4 (a version of the apolipoprotein E gene that is the strongest common genetic risk factor for late-onset Alzheimer’s) interacts directly with humanin variants. A rare humanin variant, P3S, is enriched among centenarians who also carry APOE4 and appears to neutralize APOE4-driven brain pathology in mouse models (Humanin variant P3S is associated with longevity in APOE4 carriers and resists APOE4-induced brain pathology). A published commentary notes that the variant is common in a much larger non-Ashkenazi population in which no benefit has been demonstrated (Humanin P3S, haplogroup N1b and the risk of Alzheimer’s disease), so the interaction is real but its generality is unproven.
Naturally occurring potent variants: people in mitochondrial haplogroup U6a7a1a carry the m.A2672G mutation and therefore produce S14G-humanin — the potent analog used in nearly all animal experiments — endogenously. Whether this confers any measurable advantage has never been tested, and it is the most direct natural experiment available on the question.
Baseline humanin level and mitochondrial DNA copy number: circulating humanin correlates with mitochondrial DNA copy number in blood cells and is inversely correlated with the proportion of mutated mitochondria in cells carrying mitochondrial disease mutations. Individuals with low baseline levels and low copy number are the group in whom restoration would plausibly matter most; those already at the high end may have nothing to gain and, on the strain-marker reading, may already be signaling distress.
Baseline metabolic markers: human studies report humanin inversely correlated with long-term blood sugar and triglycerides. The metabolic benefits seen in rodents were largest in models of established insulin resistance and obesity, suggesting that a metabolically healthy person has less room to improve.
Sex-based differences: the two best-characterized tissue effects are sex-specific — germ cell protection in the testis, and granulosa cell and follicular fluid effects in the ovary. The aged-mouse healthspan experiment used only female mice, and the rodent pharmacokinetic work used only males, so neither dataset has been shown to generalize across sexes. Women with polycystic ovary syndrome and insulin resistance have lower follicular fluid humanin than those without, identifying one female-specific population with a plausible deficit (Humanin Alleviates Insulin Resistance in Polycystic Ovary Syndrome: A Human and Rat Model-Based Study).
Age at the time of use: humanin signaling is age-dependent in a way that favors older users. Injecting humanin into old mice increased AKT and ERK1/2 activation in the hippocampus, while the same treatment in young mice did not. Combined with the age-related fall in endogenous levels, this suggests the responsive population is the older end of the target range rather than the younger.
Pre-existing health conditions: coronary artery disease, chronic kidney disease requiring dialysis, mitochondrial disease and Alzheimer’s disease are all associated with lower measured humanin, marking them as conditions where a deficit exists. Conversely, active malignancy is a condition in which the same cytoprotective mechanism is expected to work against the user.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Complete Absence of Human Safety Data

There is no human dosing study, no toxicology package, no adverse event register and no maximum tolerated dose for humanin or any of its analogs. Every safety inference available is extrapolated from rodents and one porcine study, none of which were designed as toxicology studies. The mechanism of concern is not a specific toxicity but the structural one: a molecule that suppresses programmed cell death across many tissues has no way of being shown safe without human exposure data. The evidence basis for this item is the registry record itself, which is unambiguous. This is graded High because the fact is certain, not because a particular harm is proven.

Magnitude: No interventional trial administering humanin or a humanin analog to humans is registered on ClinicalTrials.gov; of the seven registered studies that reference humanin, five are observational biomarker studies and the two interventional ones manipulate exercise or anesthetic technique while measuring humanin as an outcome, enrolling 50 and 68 participants respectively.

Unregulated Supply Chain and Product Integrity

Humanin available to individuals comes exclusively from research-chemical vendors selling under “research use only” or “not for human consumption” labeling. These products sit outside pharmaceutical manufacturing standards, so the realistic failure modes are wrong peptide, wrong quantity, degraded peptide, residual synthesis solvents, and bacterial endotoxin in material intended for injection. The evidence basis is the regulatory status of the category as a whole rather than humanin-specific testing, and the risk is compounded because no independent testing organization covers this compound. Severity ranges from an inert product to injection of contaminated material.

Magnitude: Not quantified in available studies.

Medium 🟥 🟥

Tumor Promotion and Interference With Chemotherapy ⚠️ Conflicted

The property that makes humanin attractive — keeping stressed cells alive — does not distinguish between healthy and malignant cells. In mice bearing triple-negative breast cancer, systemic humanin reduced tumor cell death, accelerated tumor growth, increased spontaneous lung metastasis and impaired the effect of chemotherapy; silencing humanin had the opposite effect. Comparable chemoresistance has been shown in cells from glioblastoma (an aggressive, fast-growing brain cancer). The evidence is conflicted because other tumor-bearing animal work reports the analog protecting normal tissue — male germ cells, growth-plate cartilage and white cell counts — without blunting the anticancer action of temozolomide (Jia et al., 2019) or bortezomib (Eriksson et al., 2014), so the direction may depend on the tumor type and the chemotherapy agent. It is graded Medium rather than High because all data are preclinical, but the mechanism is direct and the authors of the breast cancer work explicitly warn against therapeutic use on this basis.

Magnitude: Systemic humanin accelerated tumor growth and spontaneous lung metastasis and blunted the antitumor effect of chemotherapy in mice with triple-negative breast cancer (Humanin Promotes Tumor Progression in Experimental Triple Negative Breast Cancer); humanin increased chemoresistance in glioblastoma cells (Mitochondrial Peptide Humanin Facilitates Chemoresistance in Glioblastoma Cells).

Suppression of the Growth Axis and Reproductive Output

Humanin sits in a reciprocal relationship with the growth hormone and IGF-1 axis: growth factors suppress humanin, and humanin suppresses growth factors. Organisms engineered to overproduce humanin — both worms and mice — are smaller, leaner and less fertile, with reduced litter size and brood size, and long-term analog treatment lowers circulating IGF-1 in aged mice. For a longevity-oriented user this is genuinely double-edged, since lower IGF-1 is also the signature of the long-lived models, but the reproductive and body-composition consequences are real and not merely theoretical. The evidence basis is transgenic and treated animals across two species.

Magnitude: Humanin-overexpressing worms and mice showed reduced body size, body fat and reproductive output; 14 months of S14G-humanin at 4 mg/kg twice weekly significantly lowered circulating IGF-1 in aged mice.

Low 🟥

Amplification of Senescent Cell Inflammatory Output ⚠️ Conflicted

Rather than clearing senescent cells, humanin may preserve them and increase the inflammatory cocktail they secrete. The proposed mechanism is that the same cytoprotection that rescues healthy cells is permissive for continued cytokine production by cells that should have been eliminated. The evidence basis is a single reported dataset discussed in a review, so the grade is Low, but the implication for a longevity user is significant, since senescent cell burden and its inflammatory output are among the mechanisms such a user is typically trying to reduce. It is flagged as conflicted because the opposite direction is also reported: human macrophages clearing dead cells release humanin to drive the resolution phase of inflammation, and long-term analog treatment lowered inflammatory markers in aged mice, so the same peptide appears pro-inflammatory in one cell context and resolving in another.

Magnitude: In senescent cells, humanin and MOTS-c increased secretion of interleukin-6, interleukin-1β, interleukin-8, interleukin-10 and tumor necrosis factor alpha.

Perturbation of the IGFBP-3 Carrier System

Humanin binds IGFBP-3, the principal carrier protein that determines how much IGF-1 reaches tissues. Injecting the analog lowers both IGF-1 and IGFBP-3 over subsequent hours, meaning humanin does not simply add a signal but redistributes an existing endocrine system. The evidence basis is rodent pharmacokinetics with genetic knockout controls, which is mechanistically clean but tells nothing about human magnitude or duration. Reversibility is expected given the short half-life, but repeated dosing has not been studied for this endpoint.

Magnitude: After a single injection of S14G-humanin in mice, both IGF-1 and IGFBP-3 declined progressively over the following hours.

Because humanin has no oral bioavailability, any practical use involves subcutaneous injection (under the skin), carrying the standard risks of that route: injection site pain, erythema (redness), induration (a firm, thickened patch of skin), sterile abscess (a pocket of fluid without infection) and, with non-sterile material, local or systemic infection. The evidence basis is the general injectable peptide literature rather than humanin-specific reports, since no adverse event reporting system covers this compound. Severity is usually minor and self-limiting, but infection risk is elevated relative to pharmaceutical products because the source material is not manufactured sterile.

Magnitude: Not quantified in available studies.

Speculative 🟨

Immunogenicity and Anti-Peptide Antibody Formation

Repeated injection of a synthetic peptide, particularly a modified analog such as S14G-humanin or the fusion peptide colivelin, can provoke antibodies that neutralize both the injected peptide and the person’s own endogenous humanin. No controlled data exist; the basis is mechanistic reasoning from the general behavior of therapeutic peptides, with no isolated human reports available because no human has been studied.

Consequences of Chronic gp130 and STAT3 Activation

Sustained activation of gp130 and STAT3 is implicated in tumorigenesis, fibrosis and chronic inflammatory states in other contexts. Continuous rather than intermittent humanin exposure would drive this pathway persistently. No study has examined chronic receptor stimulation by humanin, and the concern rests entirely on what is known about the pathway from other agonists.

Suppression of Beneficial Apoptosis and Mitophagy

Programmed cell death and the selective removal of damaged mitochondria are quality-control mechanisms, not merely damage. Blocking them broadly could permit the survival of cells carrying damaged mitochondrial genomes or accumulated mutations. The basis is mechanistic inference from humanin’s known targets, and it sits against the opposite observation that humanin induces autophagy and sustains autophagic flux rather than suppressing it; no experiment has directly measured mutational burden or the selective removal of damaged mitochondria under chronic humanin exposure.

Risk-Modifying Factors

Mitochondrial haplogroup and endogenous variant status: individuals already producing a potent natural variant such as S14G-humanin (haplogroup U6a7a1a) or P3S (haplogroup N1b) would be layering exogenous peptide onto an already-elevated signal, plausibly shifting the balance toward the growth-suppressive and senescence-preserving risks rather than the protective benefits.
APOE4 carrier status: because the P3S variant interacts specifically with APOE4, and because the neuroprotective benefit appears strongest in that genetic context, APOE4 status is likely to modify both the benefit and the risk profile. Neither direction has been tested in humans.
Baseline humanin and inflammatory markers: a person whose baseline humanin is already high — which, on the mitokine reading, indicates mitochondrial strain — may be in the group where higher levels predicted worse function and shorter survival. A high baseline high-sensitivity C-reactive protein (a general blood marker of body-wide inflammation) alongside high humanin is the specific pattern that should raise concern about the senescence-amplification risk.
Baseline IGF-1: individuals already at the low end of the age-adjusted IGF-1 range have less margin before humanin’s growth-axis suppression produces unwanted loss of lean mass, bone density or wound-healing capacity.
Sex-based differences: the toxicology base is sex-segregated and incomplete. Rodent pharmacokinetics were established only in males; the long-term aged-mouse safety observations came only from females. Reduced litter size in transgenic models is a female-specific reproductive signal, and reduced brood size in worms points the same way, while the testicular data suggest male germ cells are protected rather than harmed. Neither sex has an adequate dataset.
Active or prior malignancy: this is the single largest risk modifier. Anyone with an active cancer, a cancer in remission within the last five years, an untreated precursor lesion, or a strong hereditary cancer syndrome faces the tumor-promotion and chemoresistance risk directly rather than theoretically.
Reduced renal clearance: peptides are cleared substantially by the kidney. Chronic kidney disease alters circulating humanin, and dialysis patients show a disturbed humanin profile linked to cardiovascular risk (Unbalanced circulating Humanin levels and cardiovascular risk in chronic hemodialysis patients: a pilot, prospective study). Reduced clearance would prolong exposure unpredictably in a molecule with no established therapeutic window.
Age-related considerations: older adults sit at both extremes. They have the lowest endogenous levels and the most responsive hippocampal signaling, but also the highest prevalence of undetected malignancy and of accumulated senescent cell burden — the two conditions under which humanin’s cytoprotection is most likely to work against them. The risk-benefit balance at the older end of the target range is therefore genuinely uncertain rather than uniformly favorable.

Key Interactions & Contraindications

Cytotoxic chemotherapy (cyclophosphamide, doxorubicin, cisplatin, paclitaxel): absolute contraindication during curative-intent treatment. Clinical consequence is reduced tumor cell kill and accelerated progression, demonstrated directly in animal models of triple-negative breast cancer and in glioblastoma cells. No mitigating action makes this acceptable; the interaction is the mechanism working as designed on the wrong cells.
Growth hormone and growth hormone secretagogues (recombinant somatropin, tesamorelin, CJC-1295, ipamorelin, sermorelin): secretagogues are drugs that push a gland to release more of a hormone it already makes, in this case growth hormone. Caution applies, with a bidirectional and partly self-canceling interaction. Growth hormone and IGF-1 suppress endogenous humanin, while humanin suppresses IGF-1 and IGFBP-3. The clinical consequence is unpredictable net effect on the growth axis. Mitigating action is to separate the two by at least several weeks and to measure IGF-1 before and after rather than assuming additivity.
Insulin and insulin secretagogues (insulin glargine, glipizide, glyburide, repaglinide): caution, with risk of hypoglycemia (blood sugar falling below the safe range, causing shakiness, confusion or, at the extreme, loss of consciousness). Insulin secretagogues push the pancreas to release more insulin. Humanin both sensitizes tissues to insulin and increases glucose-stimulated insulin secretion, so effects are additive. Mitigating action is more frequent glucose monitoring during the first two weeks and pre-emptive downward adjustment of secretagogue dose by the prescribing physician.
Other glucose-lowering agents (metformin, semaglutide, tirzepatide, empagliflozin): monitor. Clinical consequence is additive glucose lowering, generally without hypoglycemia for these classes used alone, but meaningful when they are combined. Mitigating action is to avoid initiating humanin within four weeks of a dose change in any of these agents so that effects remain attributable.
Over-the-counter medications: monitor rather than avoid. Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) and aspirin have no known pharmacokinetic interaction — humanin is not metabolized by the cytochrome P450 enzymes these agents affect — but low-dose aspirin generates aspirin-triggered lipoxins that act at FPR2, the same receptor humanin uses, raising a theoretical competition at that receptor with unknown consequence. Over-the-counter antihistamines, proton pump inhibitors (drugs that shut down stomach acid production) and paracetamol have no plausible interaction.
Glucose-lowering supplements (berberine, chromium picolinate, alpha-lipoic acid, cinnamon extract, bitter melon, Gymnema sylvestre): these have additive effects with humanin’s insulin-sensitizing action. Severity is caution; clinical consequence is symptomatic hypoglycemia in someone already using an insulin secretagogue. Mitigating action is to hold the supplement regimen constant while introducing humanin.
Other mitochondrial and cytoprotective peptides (MOTS-c, SS-31/elamipretide, small humanin-like peptide 2): caution due to overlapping and partly identical mechanisms. MOTS-c shares the senescence-amplifying signal reported for humanin, so concurrent use plausibly compounds that specific risk rather than adding independent benefits. Mitigating action is to use one mitochondrial peptide at a time so that any adverse signal is attributable.
Senolytic protocols (dasatinib plus quercetin, fisetin): caution regarding sequencing; senolytics are a drug class intended to clear senescent cells. If humanin preserves senescent cells, concurrent use could work directly against a senolytic cycle. The mitigating action proposed in the senescence literature is serial rather than concurrent use — senolytic first, cytoprotective peptide afterwards.
Populations who should avoid humanin:
- Anyone with active malignancy, or any cancer in remission for less than five years, or an untreated premalignant lesion, or a known hereditary cancer syndrome (BRCA1/BRCA2, Lynch syndrome).
- Anyone currently receiving or about to receive chemotherapy or radiotherapy with curative intent.
- Pregnancy, lactation, and anyone actively attempting conception, given reduced litter size and brood size in overexpressing animals and the complete absence of reproductive toxicology.
- Children and adolescents who have not completed growth, given reduced body length and body weight in overexpressing models.
- Anyone with chronic kidney disease at estimated glomerular filtration rate below 30 mL/min/1.73 m², where peptide clearance is substantially impaired and no dose adjustment data exist.
- Anyone with an active proliferative disorder such as untreated proliferative diabetic retinopathy (diabetes-driven growth of fragile new blood vessels in the retina), where blocking apoptosis in proliferating tissue is mechanistically counterproductive.

Risk Mitigation Strategies

Cancer screening before and during use: the tumor-promotion signal is the most serious identified risk, and it is partly manageable by ensuring no occult malignancy is present. This means completing all age-appropriate screening — colonoscopy, mammography or breast imaging, prostate-specific antigen, skin examination, low-dose chest computed tomography for those with smoking history — within twelve months before starting, and repeating on schedule during use rather than deferring. It mitigates the risk of unknowingly accelerating an undetected tumor.
Absolute exclusion during oncological treatment: stopping at least four weeks before and throughout any chemotherapy or radiotherapy course, and not resuming until oncological follow-up is complete, mitigates the demonstrated chemoresistance and impaired antitumor response.
Sourcing verification before first use: requiring a batch-specific certificate of analysis showing high-performance liquid chromatography purity of at least 98%, mass spectrometry confirmation of the correct molecular weight, and a bacterial endotoxin result below 5 endotoxin units per kilogram of body weight per hour mitigates the wrong-peptide, degraded-peptide and contaminated-injectate failure modes. Material without all three should be treated as unidentified.
Single-variable introduction with a defined observation window: starting humanin alone, with no other new peptide, supplement or medication change in the preceding four weeks and the following eight weeks, mitigates the risk of attributing an adverse effect to the wrong agent — a particular problem given the overlapping mechanisms of MOTS-c and SS-31.
Conservative starting exposure and slow escalation: in the absence of any human dose, beginning at the lowest quantity a vendor supplies, dosing no more than twice weekly to match the only long-term animal schedule tested, and holding that exposure for at least eight weeks before any increase mitigates the risk of an unrecognized dose-dependent toxicity in a molecule with no established ceiling.
Glucose monitoring during initiation: checking fasting glucose daily and, for anyone on insulin or a sulfonylurea (the oldest class of insulin-releasing tablets, such as glipizide or glyburide), using continuous glucose monitoring for the first fourteen days mitigates the hypoglycemia risk created by additive insulin sensitization and enhanced insulin secretion.
IGF-1 and body composition tracking: measuring IGF-1 at baseline, 12 weeks and 6 months, and tracking lean mass by dual-energy X-ray absorptiometry or bioimpedance every 6 months, mitigates the growth-axis suppression risk by detecting unwanted loss of lean tissue or an excessive fall in IGF-1 before it becomes symptomatic.
Inflammatory marker surveillance: measuring high-sensitivity C-reactive protein and interleukin-6 at baseline and at 12 weeks mitigates the senescence-amplification risk, since a rise in these markers on treatment is the observable signature of the mechanism reported in senescent cells.
Scheduled discontinuation windows: building in a planned break of at least four weeks every three to four months mitigates the theoretical risk of chronic gp130 and STAT3 activation and creates intervals in which endogenous apoptotic surveillance operates unopposed.
Sterile injection technique: using single-use sterile needles, bacteriostatic water for reconstitution, alcohol preparation of both vial septum and injection site, and rotation of injection sites mitigates the local and systemic infection risk that is elevated because the source material is not manufactured to sterile pharmaceutical standards.

Therapeutic Protocol

No validated human protocol exists: this is the defining fact of the section. There is no approved product, no prescribing information, no established dose, no established route, no established frequency and no established duration for humanin in humans. Everything below is either an animal reference point or a description of what people do in the absence of guidance, and none of it has been validated.
The two competing approaches: the field divides into administering an engineered analog and raising endogenous production, and neither has been shown superior because neither has been tested in humans.
- Exogenous analog administration is the approach pursued in essentially all preclinical work and in gray-market practice. It uses S14G-humanin rather than natural humanin because natural humanin is far less potent, and it requires injection.
- Endogenous elevation uses the established upstream regulators — endurance exercise, restraint of the growth hormone and IGF-1 axis, and dietary patterns associated with higher measured levels. It is slower, far less precise, and carries none of the sourcing or safety unknowns.
Preclinical dosing reference points: in the only long-term mammalian experiment, 18-month-old mice received S14G-humanin at 4 mg/kg by intraperitoneal injection (into the abdominal cavity) twice weekly for 14 months. In the porcine cardiac study, 2 mg/kg was given intravenously at reperfusion. Scaling these figures directly to a human dose by body size — allometric conversion, the standard arithmetic used to translate animal doses between species — is not a validated procedure and would not account for interspecies differences in clearance already documented between rats and mice.
Who developed each approach: the analog approach originates with the Keio University group of Nishimoto and Hashimoto, who discovered the peptide and produced S14G-humanin and colivelin, and was carried into aging research by Pinchas Cohen’s laboratory at the USC Leonard Davis School of Gerontology, which also generated the commercial development program. The endogenous-elevation framing comes largely from the exercise physiology and caloric restriction literature and has no single originator.
Route of administration: humanin is a peptide with no oral bioavailability and is destroyed by digestive enzymes, so oral products are pharmacologically implausible. Animal work uses intraperitoneal, intravenous, subcutaneous and intracerebroventricular (directly into the fluid-filled spaces of the brain) routes. Intranasal delivery has been explored specifically to reach the brain, in both colivelin models and a Parkinson’s model (Intranasal delivery of mitochondrial protein humanin rescues cell death and promotes mitochondrial function in Parkinson’s disease), because peripherally injected peptide is undetectable in brain tissue.
Half-life and its consequences: circulating humanin has a half-life of approximately 30 minutes. The authors of the mouse lifespan study explicitly cite this as a possible reason their twice-weekly schedule improved healthspan but not lifespan. The non-IGFBP-3-binding analog HNGF6A persists longer, and rats clear the peptide more slowly than mice.
Single versus split dosing: the short half-life argues strongly for frequent administration or a long-acting formulation, yet the only long-term animal protocol used twice-weekly bolus dosing and still produced measurable metabolic effects. The reason a 30-minute peptide produces effects lasting days is not established, and this discrepancy is unresolved rather than explained.
Best time of day: no chronobiological data exist for humanin. The only timing signal available is that endurance exercise raises circulating humanin acutely, with measurements taken at 30 minutes and 3 hours after exercise, which would place any exercise-based endogenous strategy in the post-exercise window.
Genetic factors influencing protocol choice: mitochondrial haplogroup determines which humanin variant a person already produces. Carriers of the m.A2672G variant produce S14G-humanin endogenously and would be adding more of the identical molecule; carriers of rs2854128 produce less humanin overall. APOE4 carriers are the subgroup in which the P3S variant shows benefit, making APOE4 genotyping the most informative single test before considering use.
Sex-based differences in protocol: no dosing data exist for either sex in humans. The available animal work is split — long-term dosing studied only in females, pharmacokinetics only in males — so neither a male nor a female protocol can be derived from it. The reproductive signals differ in direction between sexes and would need to be weighed separately.
Age-related considerations: hippocampal responsiveness to humanin is present in old mice and absent in young ones, and endogenous levels fall with age, both of which argue that any rationale for use strengthens with age. Against this, the mouse experiment that started in mid-life produced no lifespan benefit, and its authors suggest that may reflect starting too late — an unresolved tension with no human data to arbitrate it.
Baseline biomarkers influencing response: low measured humanin, low mitochondrial DNA copy number, elevated fasting insulin and elevated triglycerides describe the profile in which preclinical benefit was largest. High baseline humanin with elevated inflammatory markers describes the profile associated with worse outcomes in the mitokine cohort.
Pre-existing conditions influencing response: established insulin resistance, coronary artery disease and mitochondrial disease are the states with documented humanin deficits and therefore the largest theoretical response. Active malignancy inverts the entire risk-benefit calculation.

Discontinuation & Cycling

Lifelong versus short-term use: neither has been established, and the underlying biology does not settle it. The longevity rationale implies indefinite use to counteract an age-related decline, while every documented risk — tumor promotion, senescence preservation, growth-axis suppression — accumulates with duration. The only long-term mammalian exposure ran 14 months and produced healthspan gains without lifespan gain, which is a weak argument for indefinite use.
No known withdrawal effects: no withdrawal syndrome has been reported for humanin or its analogs, and none would be expected pharmacologically. Endogenous production is not suppressed by exogenous peptide in any documented feedback loop, and the 30-minute half-life means circulating exogenous peptide is gone within hours of the last dose.
No tapering protocol is required or defined: because there is no receptor downregulation data and no dependence mechanism, abrupt cessation carries no identified risk. Any effects on IGF-1 and IGFBP-3 would be expected to reverse over days to weeks as those proteins turn over, though this has not been measured after discontinuation.
Cycling has a mechanistic rationale but no supporting data: the arguments for cycling are the theoretical risk of chronic gp130 and STAT3 stimulation, the desirability of intervals in which apoptotic surveillance of damaged cells operates unopposed, and the possibility of receptor desensitization with continuous exposure. A common structure derived from these arguments — roughly three months on, one month off — has no experimental basis in the humanin literature, and the only long-term animal study used continuous twice-weekly dosing without breaks.
Efficacy maintenance is unstudied: whether the metabolic effects seen in animals persist, diminish or require escalating exposure over time has never been examined. The mouse study reported sustained differences in body composition over 14 months without dose escalation, which is the only relevant observation and is a single result in a single sex of a single strain.

Sourcing and Quality

No pharmaceutical or compounded source exists: humanin is not an approved drug in any jurisdiction, is not a dietary supplement ingredient, and is not on the bulk drug substances lists that permit compounding pharmacies to prepare it. There is consequently no legitimate pharmacy, no reputable supplement brand and no regulated manufacturer to recommend. Anyone obtaining humanin is obtaining it from a research-chemical vendor.
What “research use only” actually means: vendors sell under labeling that disclaims human use. That label is not a formality — it is the legal basis on which the product escapes pharmaceutical manufacturing requirements, meaning no requirement for sterility, identity verification, potency assay, stability testing or impurity limits.
Certificate of analysis requirements: the minimum meaningful documentation is a batch-specific certificate showing high-performance liquid chromatography purity of at least 98%, mass spectrometry confirming the expected molecular weight for the specific sequence ordered, and a bacterial endotoxin assay result. A generic certificate not tied to the batch number on the vial provides no information about the vial in hand.
Independent verification is the only real safeguard: because vendor-supplied certificates cannot be audited, third-party testing through an independent analytical laboratory on the actual received batch is the only way to confirm identity and purity. Several laboratories offer this service directly to individuals, and the cost is a meaningful fraction of the product cost.
Exact molecule specification: this matters more than for most compounds, because “humanin” from a vendor may be the natural 24-amino-acid sequence, the 21-amino-acid mitochondrial form, S14G-humanin, HNGF6A, or colivelin. These differ substantially in potency, half-life and IGFBP-3 binding, and almost all published in vivo evidence used S14G-humanin. A product labeled simply “humanin” without a sequence specification is not identifiable.
Formulation and storage: the material is supplied lyophilized (freeze-dried) and requires reconstitution, conventionally with bacteriostatic water, before injection. Lyophilized peptide is stable at −20 °C for extended periods; once reconstituted it degrades and requires refrigeration and use within weeks. Peptides shipped without cold chain and stored improperly may be substantially degraded before first use, with no way to detect this visually.
Counterfeit and substitution risk: the combination of high price, no regulatory oversight and no consumer-accessible identity test makes substitution with a cheaper peptide or with inert filler commercially attractive and difficult to detect. This is a structural feature of the market rather than a failing of particular vendors.

Practical Considerations

Time to effect: unknown in humans, and the animal data offer no short-term marker to watch. In aged mice, body weight differences emerged over months and body composition differences were measured at 10 months of treatment. Nothing in the literature suggests a perceptible acute effect, which means there is no early feedback signal to indicate whether the material is even active — a significant practical problem given the sourcing uncertainty.
Common pitfalls: assuming an animal dose converts directly to a human dose; buying a product labeled “humanin” without specifying which of five distinct molecules is wanted; conflating humanin with MOTS-c or SS-31 because all three are described as mitochondrial peptides; expecting an oral formulation to work; interpreting a laboratory humanin measurement as meaningful when the available assays cannot separate mitochondrial humanin from nuclear pseudogene products; and administering multiple novel peptides concurrently so that no adverse effect can be attributed.
Regulatory status: humanin has no approved indication anywhere and is not undergoing registered clinical development as a therapeutic in humans. It is not off-label use of an approved drug — that category does not apply, because no approved humanin product exists. It is not a legal dietary supplement ingredient. Sale for human use would be unlawful in most jurisdictions, which is precisely why it is sold as a research chemical. Personal importation is a further regulatory exposure that varies by country.
Cost and accessibility: humanin is expensive relative to conventional supplements and is available only through online research-chemical vendors and a small number of clinics operating outside standard practice. Practical accessibility is limited less by price than by the impossibility of verifying what has been purchased, and adding independent batch testing — the only meaningful safeguard — increases the effective cost substantially.
Measurement is not clinically available: humanin assays are in-house research enzyme-linked immunosorbent assays developed by individual laboratories, not validated clinical tests. No commercial laboratory offers a humanin measurement to consumers or physicians, so tracking the intended target directly is not possible.

Interaction with Foundational Habits

Sleep: the relationship is indirect and unstudied in either direction. No study has examined humanin and sleep architecture, and humanin has no known stimulant, sedative or circadian activity, so there is no expected effect on sleep onset or quality. The indirect connection runs the other way: sleep restriction impairs mitochondrial function and insulin sensitivity, the systems humanin is proposed to support, so poor sleep plausibly increases the mitochondrial strain that raises endogenous humanin. Practically, there is no timing consideration relative to bedtime.
Nutrition: the interaction is direct and works through the growth axis, giving a clear practical handle. Because growth hormone and IGF-1 suppress humanin, dietary patterns that lower IGF-1 — protein moderation, periodic fasting, fasting-mimicking approaches — would be expected to permit higher endogenous humanin, though this specific chain has not been measured end to end. There is direct observational evidence for one dietary pattern: Mediterranean diet adherence is associated with mitochondrial microproteins Humanin and SHMOOSE; potential role of the Humanin-Nox2 interaction in cardioprotection found higher circulating humanin in people with high adherence. No nutrient depletion by humanin has been reported, and no food needs to be avoided.
Exercise: the interaction is direct, potentiating and mode-specific, and this is the best-documented lifestyle lever available. A randomized comparison of exercise modes found that 45 minutes of cycling at 70% of estimated maximal oxygen uptake significantly raised circulating humanin, while a resistance session of four sets of seven repetitions on leg press and knee extension did not (Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans). Notably, resting humanin levels did not correlate with maximal oxygen uptake or strength, so this is an acute response to an endurance bout rather than a training adaptation. There is no evidence humanin blunts hypertrophy, and the muscle-cell data point the opposite way. The practical consideration is that endurance sessions, not resistance sessions, are the ones that move this marker.
Stress management: the interaction is indirect but with one concrete mechanistic link — glucocorticoids. Humanin protects against glucocorticoid toxicity in animals and attenuates dexamethasone-induced atrophy in human muscle cells, meaning it opposes a downstream consequence of sustained cortisol elevation rather than affecting cortisol itself. No study has measured humanin’s effect on the hypothalamic-pituitary-adrenal axis (the brain-to-adrenal-gland circuit that sets cortisol output) or on subjective stress. Because chronic psychological stress drives both glucocorticoid exposure and mitochondrial strain, stress reduction sits upstream of the same pathway rather than interacting with humanin pharmacologically.

Monitoring Protocol & Defining Success

Because humanin itself cannot be measured outside a research laboratory, monitoring necessarily targets the systems humanin acts on and the risks it creates, rather than the compound. Baseline testing is completed in the four weeks before any use and functions as a decision point rather than a formality: an abnormal cancer screen or an already-low IGF-1 changes whether use is reasonable at all. Baseline samples are drawn fasting, in the morning, and before any change in exercise or diet, so that later comparisons are interpretable.

Ongoing monitoring follows a defined cadence: fasting glucose daily and a full metabolic panel at 2 weeks; the complete panel below at 12 weeks; then every 6 months while use continues. Age-appropriate cancer screening runs on its normal schedule and is not deferred.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Fasting insulin	2–5 µIU/mL	Primary target of the metabolic benefit	12-hour fast required. Conventional laboratories report up to 25 µIU/mL as normal, which is far too permissive for this purpose. Pair with fasting glucose to derive insulin resistance.
HOMA-IR	< 1.0	Composite readout of insulin resistance	HOMA-IR means homeostatic model assessment of insulin resistance, calculated from paired fasting glucose and insulin. Conventional thresholds sit at 2.5–3.0; functional practice targets below 1.0.
Fasting glucose	75–86 mg/dL	Detects both the intended effect and hypoglycemia risk	12-hour fast. Check daily for the first 2 weeks, and continuously if using insulin or a sulfonylurea. Conventional normal extends to 99 mg/dL.
HbA1c	4.8–5.4%	Longer-term glycemic control, and the marker inversely correlated with humanin in human studies	HbA1c means glycated hemoglobin, reflecting average blood sugar over roughly 3 months. No fasting needed. Falsely low in anemia or shortened red cell survival.
IGF-1	Mid-range for age and sex, avoiding the lowest quartile	Detects growth-axis suppression, the most consistent systemic effect of humanin in animals	IGF-1 means insulin-like growth factor 1. Best drawn in the morning, fasting. Interpret only against age- and sex-specific reference ranges; an absolute number is meaningless without them.
IGFBP-3	Within the age-adjusted reference range, interpreted as a ratio to IGF-1	Humanin binds this carrier protein directly, so it is the most mechanistically specific marker available	IGFBP-3 means insulin-like growth factor binding protein 3. Draw with IGF-1 on the same sample; the ratio is more informative than either value alone.
hs-CRP	< 0.5 mg/L	Detects the senescence-amplification risk	hs-CRP means high-sensitivity C-reactive protein, a general blood marker of body-wide inflammation. Invalid within 2 weeks of any infection, injury or intense unaccustomed exercise. Conventional cardiovascular cut-off is 3.0 mg/L.
Interleukin-6	< 2 pg/mL	Second inflammatory marker, and one of the cytokines specifically reported to rise with humanin in senescent cells	Interleukin-6 is an inflammatory messenger protein. Morning draw preferred as levels vary through the day. Not offered by all laboratories; order with hs-CRP.
Triglycerides	< 80 mg/dL	Inversely correlated with humanin in human observational data	12-hour fast is essential; a non-fasting sample is uninterpretable. Conventional laboratories call anything below 150 mg/dL normal, which is far too permissive here. Best paired with HDL cholesterol (high-density lipoprotein cholesterol) as a triglyceride-to-HDL ratio.
ApoB	< 80 mg/dL (< 60 mg/dL if at elevated cardiovascular risk)	Cardiovascular risk tracking, given humanin’s proposed vascular effects	ApoB means apolipoprotein B, a direct count of atherogenic particles. Fasting not strictly required. Conventional cut-offs sit near 90 mg/dL for average risk and up to 130 mg/dL in some laboratory ranges. More informative than LDL cholesterol (low-density lipoprotein cholesterol) when triglycerides are elevated.
eGFR and creatinine	eGFR > 90 mL/min/1.73 m²	Peptide clearance depends on renal function, and reduced clearance prolongs exposure unpredictably	eGFR means estimated glomerular filtration rate, a calculated measure of kidney filtering capacity. Conventional practice treats anything at or above 60 mL/min/1.73 m² as normal, which leaves a wide band of reduced clearance unflagged. Creatinine is raised by high muscle mass and by creatine supplementation; cystatin C is the better measure in muscular individuals.
ALT and AST	ALT < 25 U/L (men), < 20 U/L (women)	General safety screen for an unstudied compound	ALT and AST are liver enzymes released when liver cells are stressed. Conventional upper limits near 40 U/L are too permissive. Transiently raised by intense exercise in the preceding 72 hours.
Complete blood count	Within reference range, with attention to lymphocyte count	Humanin protects lymphocytes from cytotoxic injury in animals, making this the most relevant hematological readout	No fasting required. Interpret the lymphocyte count against the individual’s own baseline rather than the population range.

Qualitative markers are tracked alongside the laboratory panel, since they are the only feedback available in the first months and none of the laboratory markers respond quickly. A simple weekly written record is sufficient.

Cognitive clarity and working memory: the domain with the strongest preclinical rationale. Best tracked with a repeatable timed task rather than impression.
Sleep quality and duration: monitored as a confounder rather than an expected effect, since any change is more likely to reflect something else.
Energy and exercise capacity: perceived exertion at a fixed submaximal workload is more informative than subjective energy.
Body composition by feel and fit of clothing: the animal data predict visceral fat loss with preserved or increased lean mass, which is detectable this way before it is measurable.
Recovery from training sessions: relevant given the muscle and glucocorticoid findings.
Injection site condition: persistent induration, erythema or nodule formation at the site is the earliest sign of a product quality problem.

Emerging Research

Humanin as a perioperative and organ-injury biomarker: the largest completed human study measured humanin isoforms in cardiac muscle and plasma against major complications after cardiac surgery in 106 patients (NCT03431844, completed 2019, University of Tartu). This line treats humanin as a readout of mitochondrial reserve rather than as a therapy, and it is currently the most productive direction because it requires no dosing safety package.
Acute kidney injury diagnostics: two registered observational studies test whether plasma humanin predicts acute kidney injury and its short-term prognosis — one in a general acute kidney injury population of 60 patients (NCT06105229) and one specifically after heart transplantation, also 60 patients (NCT06125249). Both were registered by Chinese centers with primary completion dates in 2024 and both carry unknown status, so their results may never appear.
Anesthetic technique and mitochondrial peptide response: a recruiting interventional trial of 68 renal transplant patients compares general anesthesia against combined spinal-epidural anesthesia, with humanin and MOTS-c levels alongside markers of ferroptosis (an iron-dependent form of cell death) as endpoints (NCT07678073, University of Gaziantep, primary completion October 2026). It is one of only two registered trials in which an intervention is manipulated and humanin measured as a response variable, and the only one manipulating a pharmacological variable rather than exercise.
Exercise as an endogenous lever: a recruiting trial of 50 participants with chronic kidney disease examines high-intensity exercise in dialyzed and conservatively managed patients (NCT07438002, primary completion September 2026), extending the acute exercise findings into a chronically ill population with documented humanin disturbance.
Delivery routes that reach the brain: because peripherally injected humanin is undetectable in brain tissue, the practical translational bottleneck is delivery. Intranasal administration has now shown activity in a Parkinson’s model (Intranasal delivery of mitochondrial protein humanin rescues cell death and promotes mitochondrial function in Parkinson’s disease), and nanoparticle formulations have been developed for the retina. This work could change the current understanding substantially, because most neuroprotective claims currently rest on models where the peptide was placed directly where it was needed.
Resolving the pseudogene measurement problem: the family of nuclear humanin-like genes catalogued by Zhu et al., 2022 produces near-identical peptides that current antibody assays cannot separate from mitochondrial humanin. Mass-spectrometry-based assays capable of distinguishing them would either confirm or substantially undermine the entire human observational literature, including the centenarian, cognitive aging and coronary disease findings. This is the single research direction with the greatest capacity to weaken the case.
Evidence that could weaken the case further: the tumor promotion finding in triple-negative breast cancer of Moreno Ayala et al., 2020 and the chemoresistance finding in glioblastoma of Peña Agudelo et al., 2023 both invite replication in additional tumor types. If the effect generalizes, it would constrain humanin’s use far more tightly than any efficacy result would expand it. Similarly, the senescence amplification report from Mendelsohn & Larrick, 2018 has not been independently replicated, and a confirmatory study would materially change the risk assessment for longevity-oriented users.
Evidence that could strengthen the case: the P3S variant work of Miller et al., 2024 suggests a genetically defined subgroup — APOE4 carriers — in whom a specific humanin variant confers measurable protection. Extending the analysis to the much larger non-Ashkenazi population carrying the same mutation, as proposed in Logan, 2024, would test whether that protection is general or population-specific, and a positive result would be the strongest human evidence the field has produced.
The unanswered mammalian lifespan question: the humanin-transgenic mouse line exists but its lifespan has not been reported. Its authors state in Yen et al., 2020 that they predict an increase based on the worm data. That experiment, when published, will be the most direct available test of whether lifelong elevated humanin extends mammalian life, and a null result would sharply limit the longevity rationale.

Conclusion

Humanin is a short protein fragment built from mitochondrial genes that circulates in the blood and appears to carry news about mitochondrial condition to the rest of the body. Laboratory work across cells and animals consistently shows it keeping stressed cells alive, and blood measurements in people link higher amounts to exceptional family longevity, slower loss of thinking ability, and lower rates of heart disease. Against this sits a large study in which the same signal rose with age alongside weaker grip strength and shorter survival among the very old, and animal work showing it shields tumor cells as readily as healthy ones and blunts cancer treatment.

The evidence base is unusual in two respects. Almost none of it involves giving humanin to people: the trial registry holds only measurement studies, so no human dosing, safety or side-effect record exists at all. And a large share of the foundational work comes from a single research program whose senior scientists held equity in a company created to commercialize these molecules, an interest disclosed in the papers themselves but one that shaped which questions were pursued and which molecules were engineered.

What emerges is a biologically compelling signal with strong laboratory support, an unresolved question about whether more of it protects or merely marks strain, no way to measure it outside a research laboratory, and a supply route that runs entirely through unregulated vendors selling material labeled unfit for human use.

Top - Benefits - Risks - Protocol

Humanin for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Association With Exceptional Longevity and Slower Cognitive Aging ⚠️ Conflicted

Neuroprotection Against Alzheimer-Type and Ischemic Injury

Improved Insulin Sensitivity and Body Composition ⚠️ Conflicted

Low 🟩

Cardioprotection in Ischemia–Reperfusion Injury ⚠️ Conflicted

Prevention of Age-Related Myocardial Fibrosis

Preservation of Endothelial Function and Restraint of Plaque Progression

Protection of Bone Growth and Restraint of Bone Resorption

Protection of Retinal Pigment Epithelium

Protection of Reproductive Tissue and Gamete Quality ⚠️ Conflicted

Resolution of Inflammation ⚠️ Conflicted

Induction of Autophagy and Clearance of Misfolded Proteins

Speculative 🟨

Extension of Lifespan

Preservation of Skeletal Muscle Mass

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Complete Absence of Human Safety Data

Unregulated Supply Chain and Product Integrity

Medium 🟥 🟥

Tumor Promotion and Interference With Chemotherapy ⚠️ Conflicted

Suppression of the Growth Axis and Reproductive Output

Low 🟥

Amplification of Senescent Cell Inflammatory Output ⚠️ Conflicted

Perturbation of the IGFBP-3 Carrier System

Injection-Related Local and Systemic Reactions

Speculative 🟨

Immunogenicity and Anti-Peptide Antibody Formation

Consequences of Chronic gp130 and STAT3 Activation

Suppression of Beneficial Apoptosis and Mitophagy

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion